

NON-EXECUTIVE DIRECTOR CHANGES

Adelaide, Australia, 1 March 2019: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, announces the following non-executive director changes.

Damian Lismore will join the Board as a non-executive director, starting 25th March 2019. Now based in Melbourne, Australia, Damian has held a number of directorships and has extensive commercial, international and listed company experience (both ASX and NASDAQ), covering many industries including healthcare and technology. In his executive career, he held CEO, CFO and Company Secretarial roles and continues to act as an advisor to CEOs, boards and business owners.

Dr Glenn Haifer will retire from the Board due to increased time commitments in a company he acquired at the end of 2018. Glenn has provided significant contributions since joining the Board in 2017 and will step down effective immediately.

LBT Chairman Kate Costello said:

"Damian's background in M&A, licensing and business financing within listed companies brings skills that broaden and strengthen the overall composition of the board. A global outlook remains a key focus for the company which is another competency Damian brings to the Board."

We'd like to acknowledge and thank Glenn for his contributions and wish him success in his recently acquired business."

Both Damian and recently appointed US based director, Simon Arkell, will visit Adelaide in March for a face-to-face induction and business strategy meeting.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software, and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation. LBT's third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com